Evolus (NASDAQ:EOLS) Given New $22.00 Price Target at Barclays

Evolus (NASDAQ:EOLS) had its price target lifted by Barclays from $20.00 to $22.00 in a report released on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 54.60% from the stock’s current price.

Several other equities analysts have also weighed in on EOLS. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Tuesday, January 21st.

Evolus Stock Up 1.5 %

Shares of EOLS stock opened at $14.23 on Monday. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The stock has a market cap of $901.04 million, a P/E ratio of -15.64 and a beta of 1.32. The stock has a 50 day moving average of $11.79 and a 200 day moving average of $13.81. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in EOLS. Essex Investment Management Co. LLC boosted its holdings in Evolus by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after acquiring an additional 1,111 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Evolus by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after purchasing an additional 1,291 shares in the last quarter. Creative Planning grew its holdings in shares of Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares in the last quarter. Sei Investments Co. increased its stake in Evolus by 9.8% during the 2nd quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock worth $367,000 after buying an additional 3,020 shares during the period. Finally, KBC Group NV acquired a new stake in Evolus during the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.